Kiadis Pharma N.V. - Company Profile

Realignment around acquired NK assets primed Kiadis for €308M Sanofi buyout

...late last year.Sanofi (Euronext:SAN; NASDAQ:SNY) said it intends to pay €308 million ($358.3 million) to acquire Kiadis Pharma N.V....
...offer process that typically takes about five months.Kiadis added €3.65 (249%) to €5.12 on Monday. Paul Bonanos Kiadis Pharma N.V. CytoSen...

Genzyme vet Modur joins Zikani; plus Scholar Rock, Poseida, Ribon, Kiadis and more

...of Cadent Therapeutics Inc. and also serves on the board of Aileron Therapeutics Inc. (NASDAQ:ALRN). Kiadis Pharma N.V....
...of clinical development at LogicBio Therapeutics Inc. (NASDAQ:LOGC). Robin Sawka, BioCentury Staff ViaCyte Inc. Ribon Therapeutics Inc. Innate Pharma S.A. Kiadis Pharma N.V. Zikani...

July 13 Quick Takes: Spudich, Rutter to lead start-up Kainomyx; plus deals for Ovid-Angelini, Dewpoint-Merck and Kiadis-Sanofi

...with Sarclisa Sanofi (Euronext:SAN; NASDAQ:SNY) licensed exclusive, worldwide rights to an NK cell therapy from Kiadis Pharma N.V....
...Kiadis’ platform for two other preclinical programs. BioCentury Staff gaboxadol (OV101) Cytokinetics Inc. Merck & Co. Inc. Dewpoint Therapeutics Ovid Therapeutics Inc. Angelini Sanofi Kiadis Pharma N.V. Kainomyx...

Management Tracks: Alector hires new president, COO and appoints R&D committee co-chairs; plus Pyxis, Translate Bio, Canaan, PMV, Janpix, Kiadis and more

...trigger their degradation to treat cancer (see "Janpix Picks STAT Inhibitors for Blood Cancers" ). Kiadis Pharma N.V....
...was CSO and medical director at Exagen Inc. (NASDAQ:XGN). BioCentury Staff Alector Inc. Translate Bio Inc. Janpix Inc. PMV Pharmaceuticals Inc. Canaan Kiadis Pharma N.V. Clarus...

T cell company Kiadis to acquire NK cell company Cytosen

...acquire NK cell company Cytosen in a deal valued at EUR19.4 million ($21.9 million) Additionally, Kiadis Pharma N.V....
...vivo of host alloreactive T cells using photodynamic treatment. Mary Romeo, Staff Writer ATIR (ATIR101, Theralux-ATIR) CytoSen Therapeutics Inc. Kiadis Pharma N.V. Carl...

BioCentury | Nov 3, 2020

Deals

Data Byte: NK cell therapies draw slew of partnerships in 2020

...are developing treatments for cancer and four are to creating NK cell therapies for COVID-19. Amanda Micklus Sanofi Kiadis Pharma N.V. Cell...

BioCentury | Nov 2, 2020

Deals

Realignment around acquired NK assets primed Kiadis for €308M Sanofi buyout

BioCentury | Jul 18, 2020

Management Tracks

Genzyme vet Modur joins Zikani; plus Scholar Rock, Poseida, Ribon, Kiadis and more

BioCentury | Jul 14, 2020

Deals

July 13 Quick Takes: Spudich, Rutter to lead start-up Kainomyx; plus deals for Ovid-Angelini, Dewpoint-Merck and Kiadis-Sanofi

BioCentury | Jan 17, 2020

Company News

Management tracks: Sun departs as Hengrui chair; plus Blackstone, Ipsen, bluebird, BioNTech, Catalent, Foundation, Twist, Lantheus, Abcam and more

...company Disarm Therapeutics Inc. hired Scott Holmes as its first CFO. Holmes was CFO at Kiadis Pharma N.V....

BioCentury | Dec 14, 2019

Company News

Management Tracks: Alector hires new president, COO and appoints R&D committee co-chairs; plus Pyxis, Translate Bio, Canaan, PMV, Janpix, Kiadis and more

BioCentury | Jun 29, 2019

Finance

Specialists and strong fundamentals must carry the sector in 3Q19

...UD UD UD Yourgene Health plc (LSE:YGEN) Elucigene Diagnostics Ltd. 04/18/19 $8.3 $3.8 NA $12.1 Kiadis Pharma N.V....

BioCentury | Apr 19, 2019

Company News

T cell company Kiadis to acquire NK cell company Cytosen

BioCentury | Mar 6, 2019

Company News

Management tracks: UCB Ventures, GlycoMimetics, Fluidigm

...Raises $42M Series A" ). Dirk de Naeyer will succeed Jan Feijen as COO of Kiadis Pharma N.V....

BioCentury | Feb 6, 2019

Company News

Management tracks: Astellas, Blueprint

...will retire. CEO Barry Quart will take on the additional role of president. Immunotherapy company Kiadis Pharma N.V....

Data Byte: NK cell therapies draw slew of partnerships in 2020

Realignment around acquired NK assets primed Kiadis for €308M Sanofi buyout

Genzyme vet Modur joins Zikani; plus Scholar Rock, Poseida, Ribon, Kiadis and more

July 13 Quick Takes: Spudich, Rutter to lead start-up Kainomyx; plus deals for Ovid-Angelini, Dewpoint-Merck and Kiadis-Sanofi

Management tracks: Sun departs as Hengrui chair; plus Blackstone, Ipsen, bluebird, BioNTech, Catalent, Foundation, Twist, Lantheus, Abcam and more

Management Tracks: Alector hires new president, COO and appoints R&D committee co-chairs; plus Pyxis, Translate Bio, Canaan, PMV, Janpix, Kiadis and more

Specialists and strong fundamentals must carry the sector in 3Q19

T cell company Kiadis to acquire NK cell company Cytosen

Management tracks: UCB Ventures, GlycoMimetics, Fluidigm

Management tracks: Astellas, Blueprint

Data Byte: NK cell therapies draw slew of partnerships in 2020

Realignment around acquired NK assets primed Kiadis for €308M Sanofi buyout

Genzyme vet Modur joins Zikani; plus Scholar Rock, Poseida, Ribon, Kiadis and more

July 13 Quick Takes: Spudich, Rutter to lead start-up Kainomyx; plus deals for Ovid-Angelini, Dewpoint-Merck and Kiadis-Sanofi

Management tracks: Sun departs as Hengrui chair; plus Blackstone, Ipsen, bluebird, BioNTech, Catalent, Foundation, Twist, Lantheus, Abcam and more

Management Tracks: Alector hires new president, COO and appoints R&D committee co-chairs; plus Pyxis, Translate Bio, Canaan, PMV, Janpix, Kiadis and more

Specialists and strong fundamentals must carry the sector in 3Q19

T cell company Kiadis to acquire NK cell company Cytosen

Management tracks: UCB Ventures, GlycoMimetics, Fluidigm

Management tracks: Astellas, Blueprint

Products & Solutions

About Biocentury

Contact

Privacy & Legal